Stocklytics Platform
Asset logo for symbol AGIO
Agios Pharmaceuticals
AGIO60
$44.87arrow_drop_up1.19%$0.53
Asset logo for symbol AGIO
AGIO60

$44.87

arrow_drop_up1.19%

Income Statement (AGIO)

itemJun 2024Mar 2024Dec 2023Sep 2023Jun 2023
EBIT-$105.81M-$92.07M-$106.27M-$102.52M-$95.50M
EBITDA-$104.22M-$90.72M-$104.87M-$100.89M-$93.70M
gross Profit$5.52M$6.21M$5.11M$6.76M$5.60M
NET Income-$96.11M-$81.54M-$95.94M-$91.32M-$83.80M
total Revenue$8.61M$8.18M$7.10M$7.39M$6.71M

Balance Sheet (AGIO)

itemJun 2024Mar 2024Dec 2023Sep 2023Jun 2023
cash Equivalents-----
net Debt-$19.89M-$50.41M-$16.20M$11.16M-$5.80M
stockholders Equity$660.51M$743.92M$811.01M$886.84M$964.23M
total Assets$773.06M$849.70M$937.11M$1.00B$1.08B
total Debt$64.62M$68.34M$71.99M$75.49M$78.94M
total Liabilities$112.55M$105.78M$126.09M$120.41M$120.91M

Cash Flow (AGIO)

itemJun 2024Mar 2024Dec 2023Sep 2023Jun 2023
financing Cash Flow$1.09M$5.86M$847.00K$1.88M$237.00K
free Cash Flow-$72.74M-$100.00M-$72.72M-$79.51M-$66.74M
investing Cash Flow---$39.34M$47.12M
operating Cash Flow-$72.58M-$99.86M-$72.48M-$61.64M-$66.74M

Agios Pharmaceuticals (AGIO) Financials

Agios Pharmaceuticals Inc (AGIO) is a biopharmaceutical company that focuses on discovering and developing novel medicines to treat cancer and rare genetic diseases. The company's financials provide valuable insights into its performance and position in the market. Let's take a closer look at Agios Pharmaceuticals Inc's income statement. The income statement reveals the company's revenues, expenses, and profits over a specific period. For Agios Pharmaceuticals Inc, the income statement shows its total revenue, gross profit, operating expenses, and net income from stockholders. The total revenue represents the company's overall sales during the given period, while gross profit is the difference between total revenue and the cost of goods sold. Operating expenses include research and development costs, sales and marketing expenses, and general administrative expenses. Net income from stockholders is the final profit after deducting taxes and other expenses.
Another important financial metric worth examining is EBIT, which stands for Earnings Before Interest and Taxes. EBIT measures a company's operating performance, excluding interest and tax expenses. Agios Pharmaceuticals Inc's EBIT provides insights into its profitability and efficiency in generating profits from its core business operations. Furthermore, EBITDA, which stands for Earnings Before Interest, Taxes, Depreciation, and Amortization, is another crucial financial metric. EBITDA represents a company's operating profit before accounting for non-cash expenses such as depreciation and amortization. Agios Pharmaceuticals Inc's EBITDA is a useful measure for evaluating its cash flow generation and overall financial health.
Turning our focus to the balance sheet, Agios Pharmaceuticals Inc's balance sheet provides a snapshot of its financial position at a specific point in time. It includes information about the company's assets, liabilities, and stockholders' equity. Total assets represent the company's resources, including cash, investments, property, and equipment. Liabilities, on the other hand, are the company's obligations, such as debt and accounts payable. Stockholders' equity is the residual interest in the assets after deducting liabilities. Agios Pharmaceuticals Inc's balance sheet also provides insights into its liquidity and solvency, as well as its ability to fund its operations and future growth.
Cash flow is another crucial aspect of Agios Pharmaceuticals Inc's financials. The cash flow statement shows how cash moves in and out of the company during a specific period. It provides information about the company's operating, investing, and financing activities. Operating cash flow measures the cash generated from the company's core operations, while investing cash flow represents cash flows related to investments in assets or other companies. Financing cash flow, on the other hand, shows cash flows from activities such as issuing or repurchasing stock and paying dividends. Agios Pharmaceuticals Inc's cash flow statement is an essential tool for assessing its ability to generate cash and its overall financial stability.
In conclusion, Agios Pharmaceuticals Inc's financials provide valuable insights into its performance, profitability, and financial position. By analyzing metrics such as total revenue, gross profit, net income from stockholders, EBIT, EBITDA, and cash flows, investors and stakeholders can better understand the company's financial health and potential for growth. Agios Pharmaceuticals Inc's balance sheet also offers insights into its assets, liabilities, and stockholders' equity. Overall, understanding and analyzing Agios Pharmaceuticals Inc's financials is crucial for making informed investment decisions.
add Agios Pharmaceuticals  to watchlist

Keep an eye on Agios Pharmaceuticals

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level